Decreased Expression of TRPM3 and mAChRM3 in the Small Intestine in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis

Sonya Marshall-Gradisnik¹,²*, Marshall Fretel¹,², Natalie Eaton¹,², Helene Cabanas¹,², Cassandra Balinas¹,², Vinod Gopalan¹, Daniel Petersen², Rachel Passmore¹,², Kevin Tang²,³, Mazhar Haque⁴, Alfred Lam¹, Donald Staines¹,²

¹School of Medical Science, Griffith University, Brisbane, Australia
²The National Centre for Neuroimmunology and Emerging Diseases, Menzies Health Institute Queensland, Griffith University, Brisbane, Australia
³Gold Coast University Hospital, Parklands, Australia
⁴Mater Hill Gastroenterology, South Brisbane, Australia
Email: *ncned@griffith.edu.au

Abstract

Introduction: Chronic Fatigue Syndrome/Myalgic Encephalomyelitis (CFS/ME) is often associated with gastrointestinal disturbance and inflammatory markers; however, there have been no histological studies performed in the small intestine from CFS/ME patients. The aim of this investigation was to assess the expression of certain inflammatory markers and inflammatory receptors, namely transient receptor potential melastin 3 (TRPM3) ion channels and muscarinic acetylcholine M3 (mAChRM3) receptors, in small intestinal tissues in a case controlled study comprising a CFS/ME patient and a healthy non-fatigued control.

Method: Immunohistochemistry was performed on a small intestinal biopsy from a CFS/ME patient (age = 50; female) with self-reported symptoms of gastrointestinal disturbance and a healthy non-fatigued control (NFC), (age = 28; female). Semi-quantitative analysis of expression was undertaken for interferon-gamma (IFNγ), interleukin-1 alpha (IL-1α), tumour necrosis factor-alpha (TNFα), TRPM3 ion channels and mAChRM3 acetylcholine receptors. Results: There was significantly decreased expression of TRPM3 in the CFS/ME patient (35% ± 9%) and a significant decrease in mAChRM3 in the CFS/ME patient (54% ± 9%). There was no difference in IL-1α between CFS/ME patient and NFC, however; there was an increase in IFNγ (13% ± 6%) in the CFS/ME patient compared to NFC. There was a difference observed in TNFα in CFS/ME compared to NFC. Conclusion: Differences were noted in the expression of specific TRP ion channels and cholinergic receptors in CFS/ME compared with NFC, with CFS/ME demon-
strating decreased TRPM3 and mAChRM3. Further, IFNy was increased, and TNFα decreased, in the small intestine of the CFS/ME patient with reported gastrointestinal disturbance.

**Keywords**
Chronic Fatigue Syndrome/Myalgic Encephalomyelitis, Irritable Bowel, TRPM3, mAChRM3, Small Intestine, Inflammation

**1. Introduction**

Chronic Fatigue Syndrome/Myalgic Encephalomyelitis (CFS/ME) is a complex and unexplained disorder associated with several physiological systems including the gastrointestinal (GI) tract [1] [2]. The prevalence of CFS/ME globally is uncertain, however, estimates range from 0.2% to 1.3% in primary health care [3]. In the absence of a biological marker, diagnosis is based on symptom criteria and differentiating symptoms from other conditions. Many CFS/ME patients experience GI disturbances that are hallmarks of irritable bowel syndrome (IBS) including abdominal pain and alterations in bowel habit [4] [5] [6] [7]. The pathomechanisms of GI disturbances in CFS/ME are unknown, although evidence suggests mediation by increased intestinal permeability, microbiota imbalance and persistent inflammation [1] [8] [9] [10].

Reports indicate chronic inflammation in CFS/ME is characterised by immunological dysfunction. Multiple studies describe elevated systemic levels of pro-inflammatory cytokines while others, at times in the same cohort, have observed increases in anti-inflammatory cytokines [1] [11]-[17]. The incongruence in results across studies is likely a consequence of the heterogeneous nature of CFS/ME but also an abnormal immune signature. In a network analysis of cytokine co-expression in CFS/ME, inflammatory profiles suggest an overriding Th2 response [18]. The contribution of disrupted cytokine production to GI pathology in CFS/ME is uncertain although studies indicate elevated systemic inflammation is a by-product of spill-over from foci in the gut, a possible result of microbiome dysbiosis and bacterial translocation [19] [20] [21] [22]. Evidence of impaired mucosal integrity via serum levels of IgA and IgM to enterobacteria may account for inflammation and visceral hypersensitivity in CFS/ME [21].

Transient receptor potential (TRP) ion channels are ubiquitously expressed in most tissues and physiological function depends on the location of expression. TRPs are non-selective cation permeable channels and are involved in intracellular Ca²⁺ signalling [23]. Channelopathies associated with TRP function lead to disorders/diseases including chronic pain, overactive bladder and neurosensory/motor neuropathies that parallel clinical presentation of CFS/ME [23]. TRPs are comprised of six main groups in humans: TRPA (ankyrin), TRPC (canonical), TRPM (melastatin), TRPML (mucolipin), TRPP (polycystin) and TRPV (vanilloid) [24]. Of the TRP channels, TRPM3 encodes the largest num-
ber of variants through alternative splicing events [25]. We have detected genetic anomalies in the TRPM3 gene in peripheral lymphocytes in CFS/ME [26]. Additionally, we have reported significant reduction in the expression of TRPM3 on Natural Killer cells and significant reduction in calcium stores and entry following stimulation of TRPM3 on NK cells [27] [28], which may contribute to altered Ca2+ metabolism and function [26] [27]. However, due to the difficulty of obtaining biological tissue samples from patients, there has been little avenue to assess the expression of TRPM3 on tissue other than blood cells.

Cellular distribution of nicotinic acetylcholine receptors (nAChR) and muscarinic acetylcholine receptors (mAChR) is diverse with expression in the central-, peripheral-, and autonomic nervous systems. Additionally, mAChRs are present in immune cells and tissues of the GI tract. Acetylcholine receptors (AChR), particularly mAChR M1, can inhibit TRPM3 via phospholipase C activity and potentially play a vital role in GI pathology [29] [30]. Mutations in mAChR genes may result in altered function of these receptors and we have identified single nucleotide polymorphisms (SNP) in mAChR genes in CFS/ME [30]. The functional implications of mAChR SNPs and the association with TRPM3 are still unknown [30].

To our knowledge, there are no histological studies that determine inflammation, TRPM3 ion channel and mAChR expression as well as inflammatory markers in small intestinal tissues in CFS/ME. The aim of this pilot study is to compare histological markers of inflammation and expression of TRPM3 and mAChRM3 in a CFS/ME patient compared to a non-fatigued control.

2. Methods

2.1. Participants

Clinical diagnosis of CFS/ME follows the Fukuda criteria which include unexplained fatigue often accompanied by cognitive impairment, unrefreshed sleep, headaches, myalgia, arthralgia and other flu-like symptoms [31]. Alternative diagnostic algorithms are used, i.e. the International Consensus Criteria (ICC) which comprises a range and severity of symptoms associated with neurological, immunological, autonomic and GI imbalances observed in the disorder [2]. One CFS/ME patient and one non-fatigued control (NFC) were recruited for this study. The CFS/ME patient completed a comprehensive questionnaire corresponding with the Fukuda and ICC criteria. The CFS/ME patient was clinically diagnosed as severe CFS/ME and met both Fukuda and ICC requirements. Clinical characteristics are summarised in Table 1. Participants were excluded from this study if they reported history of smoking, autoimmune diseases, cardiac disease, diabetes or other co-morbidities in addition to pregnancy or breast-feeding. A self-report survey regarding symptom frequency and severity is summarised in Table 2.

CFS/ME Patient: 50-year old female, 168 cm and 70 kg. Patient experienced mild symptoms of CFS/ME during childhood although clinical diagnosis not
Table 1. Sociodemographic and clinical characteristics.

<table>
<thead>
<tr>
<th></th>
<th>CFS/ME (n = 1)</th>
<th>NFC (n = 1)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Sociodemographic</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age (years)</td>
<td>50</td>
<td>28</td>
</tr>
<tr>
<td>Gender</td>
<td>Female</td>
<td>Female</td>
</tr>
<tr>
<td><strong>Clinical</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PENE</td>
<td>Yes</td>
<td>None</td>
</tr>
<tr>
<td>Cognitive Impairments</td>
<td>Yes</td>
<td>None</td>
</tr>
<tr>
<td>Neurosensory Disturbances</td>
<td>Yes</td>
<td>None</td>
</tr>
<tr>
<td>Body Pain</td>
<td>Yes</td>
<td>None</td>
</tr>
<tr>
<td>Headaches</td>
<td>Yes</td>
<td>None</td>
</tr>
<tr>
<td>Abdominal Pain</td>
<td>Yes</td>
<td>None</td>
</tr>
<tr>
<td>Gastrointestinal sensitivites</td>
<td>Yes</td>
<td>None</td>
</tr>
<tr>
<td>Genituourinary Disturbances</td>
<td>Yes</td>
<td>None</td>
</tr>
<tr>
<td>Nausea</td>
<td>Yes</td>
<td>None</td>
</tr>
<tr>
<td>Bloating</td>
<td>Yes</td>
<td>None</td>
</tr>
<tr>
<td>Food/medication/chemical insensitivities</td>
<td>Yes</td>
<td>None</td>
</tr>
<tr>
<td>Flu-like symptoms</td>
<td>Yes</td>
<td>None</td>
</tr>
<tr>
<td>Thermostatic Instability</td>
<td>Yes</td>
<td>None</td>
</tr>
<tr>
<td>Cardiovascular and Respiratory disturbances</td>
<td>Yes</td>
<td>None</td>
</tr>
</tbody>
</table>

Clinical characteristics outlined correspond with the CFS/ME inclusion questionnaire. Abbreviations: CFS/ME, chronic fatigue syndrome/myalgic encephalomyelitis; NFC, non-fatigued control; PENE, post-exertional neuroimmune exhaustion.

Table 2. Self-reported frequency and severity of symptoms of CFS/ME patient.

<table>
<thead>
<tr>
<th>Symptom</th>
<th>CFS/ME patient</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Frequency</td>
</tr>
<tr>
<td>Difficulty Processing Information</td>
<td>Often</td>
</tr>
<tr>
<td>Pain</td>
<td>Often</td>
</tr>
<tr>
<td>Sleep Disturbances</td>
<td>Often</td>
</tr>
<tr>
<td>Sensory Disturbances</td>
<td>Often</td>
</tr>
<tr>
<td>Flu-like/immune symptoms</td>
<td>Often</td>
</tr>
<tr>
<td>Bowel and urinary</td>
<td>Often</td>
</tr>
<tr>
<td>Cardiovascular</td>
<td>Often</td>
</tr>
<tr>
<td>Respiratory</td>
<td>Often</td>
</tr>
<tr>
<td>Thermostatic instability</td>
<td>Often</td>
</tr>
</tbody>
</table>

Frequency ranking = never, rarely, often, quite often. Severity ranking = 1 - 10; 1 = very good, 10 = poor.
made until age 39. The patient had a history of orthostatic intolerance and was on a disability pension. Self-reported symptoms include GI sensitivities and genitourinary disturbances: severe abdominal pain, nausea, bloating, food/medication/chemical insensitivities and urinary frequency and nocturia. Patient nutritional intake followed a Western Dietary pattern [32]. Medications include Movicol, melatonin, acetyl L-Carnitine, CoQ10, alpha-lipoic acid, vitamin D3, magnesium (Mg²⁺), acidophilus, B complex, multivitamin, vitamin A and fish oil. All medications were ceased 48 h prior to biopsy.

**NFC:** The NFC participant was female (age = 28) with no history of CFS/ME or immune dysfunction or inflammatory disorder, not pregnant or breast feeding and not clinically diagnosed with IBS or any gastrointestinal disorder.

All participants were residents of Australia at the time of the study. The project was approved under the Human Ethics Research Committee Griffith University (MSC/05/HREC).

### 2.2. Patient Samples

10% formalin fixed, paraffin embedded small intestinal biopsy samples were collected from NFC and CFS/ME participants at Mater Private Hospital in Brisbane and Pacific Private Hospital in Southport, QLD. Frozen tissue sections were cut (4 µm) using a Leica microtome (Leica RM2235, Wetzler, Germany) and placed on tissue adhesive microscope slides (Lamb Scientific, NSW, Australia).

### 2.3. Immunohistochemistry

In brief, slides were deparaffinised and dried with graded dilutions of xylene and alcohol. Antigen retrieval was performed in TE Buffer (Gibco, Thermofisher Scientific, Australia) at 150 W for 20 min. Endogenous peroxidase was blocked for 5 min followed by a protein block for 5 min. Tissue sections were stained using the Novolink Polymer Detection System (Leica, Wetzler, Germany) according to manufacturer instructions. Slides were incubated with polyclonal antibodies against hTRPM3 (H-300, 1/600 dilution: Santa Cruz Biotechnology Inc, USA), hmAChRM3 (H-210, 1/700 dilution: Santa Cruz Biotechnology Inc, USA), and monoclonal antibodies against IL-1α (5G3, 1/50 dilution: Santa Cruz Biotechnology Inc, USA), IFN-γ (LLO6Z, 1/50 dilution: Santa Cruz Biotechnology Inc, USA) and TNFα (52B83, 1/700 dilution: Santa Cruz Biotechnology Inc, USA). Antibodies were detected using the Novolink polymer reagent (anti-mouse/anti-rabbit IgG-poly-HRP) for 20 min followed by visualisation with DAB (3, 3’-diaminobenzidine) solution. Slides were counterstained with haematoxylin followed by Scott’s Blueing solution.

### 2.4. Image Analysis

Image analysis was performed using Apeiro software (Leica Biosystems, Wetzler, Germany). As a negative control, distilled H₂O was substituted for primary antibody. Slides were examined (40×) in 5 random fields and 100 lymphocytes
counted per field. Immunochemical staining was assessed semi-quantitatively in 4 categories: 0 to less than 5% positive (0), 5% to 30% of cells positive (1+), 31% to 60% of cells positive (2+), and 61% to 100% of cells positive (3+). Protein expression were labelled as “high” when protein expression was 2+/3+, whereas categories 0, 1+ were labelled as “low”.

3. Results
3.1. TRPM3 and mAChRM3

There was a significant reduction observed in TRPM3 in mucosal lymphocytes in the CFS/ME patient (0%) compared with the NFC (35% ± 9%). There was a significant decrease in mAChRM3 in the CFS/ME patient (0%) compared with NFC (54% ± 9%). IHC images are provided in Figure 1.

![Image](https://example.com/image)

**Figure 1.** Immunohistochemistry staining of protein expression for mAChRM3 and TRPM3 in mucosal lymphocytes in CFS/ME small intestine. Results for negative control staining provided in row 1, mAChRM3 (row 2), TRPM3 (row 3), IL-1α (row 4), IFNγ (row5) and TNFα (row 6). Results for non-fatigued control (column 1) and CFS/ME patient (column 2). Positive staining indicated by a brown precipitate in cells. Black arrows are provided to identify an example of a positive cell. All images (40×).
3.2. Inflammatory Markers

There was no difference between the CFS/ME patient (75% ± 13%) and NFC for IL-1α (69% ± 10%). In contrast, there was a significant increase in IFNγ (13% ± 6%) in the CFS/ME patient compared to NFC (0%). There was a significant difference in TNFα between the CFS/ME patient (0%) and NFC (53% ± 20%). Results of IHC expression are summarised in Table 3. IHC images are provided in Figure 1.

4. Discussions

This is the first histological case study examining pro-inflammatory cytokines, TRPM3 and mAChRM3 receptors in the small intestine of a CFS/ME patient. Overall, we observed a decrease in cytokines, TRPM3 and mAChRM3 expression in the CFS/ME patient mucosal lymphocytes compared with NFC and may justify future investigations into mucosal immune cell function and GI pathology in this illness.

Our investigation found a reduction in TRPM3 mucosal lymphocytes in the CFS/ME patient compared to NFC and supports our previous findings where TRPM3 surface expression on CD56bright NK cells and B lymphocytes was significantly reduced in CFS/ME patients compared to controls [27] [28]. In conjunction with significant reduction in TRPM3 expression on immune cells, we also reported a significant decrease in intracellular Ca^{2+} following stimulation of the TRPM3 receptor by its natural ligand, pregnenolone sulfate, as well as significantly lower intracellular Ca^{2+} stores from NK cells from CFS/ME patients. Collectively, these studies indicate the TRPM3 receptor may be dysfunctional,

Table 3. Immunohistochemistry examination of TRPM3, mAChRM3 and cytokine expression in small intestine of CFS/ME compared to NFC.

<table>
<thead>
<tr>
<th>Protein</th>
<th>High Expression (2+/3+)</th>
<th>Low Expression (0,1+)</th>
<th>Expression compared to NFC</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>TRPM3</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CFS/ME Patient</td>
<td>2+ (35%)</td>
<td>0 (100%)</td>
<td>↓</td>
<td>0.001a</td>
</tr>
<tr>
<td>Control</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>mAChRM3</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CFS/ME Patient</td>
<td>2+ (54%)</td>
<td>0 (100%)</td>
<td>↓</td>
<td>0.001a</td>
</tr>
<tr>
<td>Control</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IL-α</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CFS/ME Patient</td>
<td>3+ (69%)</td>
<td>Nd</td>
<td></td>
<td>0.599</td>
</tr>
<tr>
<td>Control</td>
<td>3+ (75%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IFNγ</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CFS/ME Patient</td>
<td>1+ (13%)</td>
<td>0 (100%)</td>
<td>↑</td>
<td>0.040a</td>
</tr>
<tr>
<td>Control</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>TNFα</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CFS/ME Patient</td>
<td>2+ (53%)</td>
<td>0 (100%)</td>
<td>↓</td>
<td>0.011a</td>
</tr>
<tr>
<td>Control</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

a Significant at α = 0.05; ND = No Difference, NFC = non-fatigued control.
resulting in dysregulation of calcium mobilisation. Importantly, this current investigation supports these findings, suggesting disturbed cell signalling mechanisms are common in CFS/ME [33] [34]. Moreover, functional studies of TRPM3 variants have also indicated the absence of specific residues that disable Ca\(^{2+}\) entry and mobilisation into cells in rodent and human tissue. Furthermore, Ca\(^{2+}\) entry in cells co-expressing TRPM3 variants and wild type TRPM3 channels has been reported to be diminished [35]. TRPM3 is involved in thermal and nociceptive sensation and abnormal responses to heat have been identified in TRPM3 knockout mice [25]. Interestingly, CFS patients report changes in thermoregulation [2] [36] [37].

In this study, we were the first to focus on TRPM3 due to our previous research reporting genetic and proteomic changes of TRPM3 in CFS/ME. The results from this research may provide evidence for the role of TRPM3 in the pathomechanism in CFS/ME. Additionally, the role of TRP receptors in the possible development of the pathomechanisms of CFS/ME may be highlighted through TRPV1 and TRPV4 mediated thermal, chemical, nociceptive and mechanosensation responses in the alimentary canal [38]. TRPV1 is prominently expressed in visceral afferent neurons in the GI tract and may mediate immune responses observed in inflammatory thermal hyperalgesia in the GI mucosa [39]. An increase in TRPV1 immunoreactivity in colonic nerve fibres of IBS patients with hypersensitivity/hyperalgesia has been reported in addition to studies demonstrating upregulation of TRPV1 in leukocytes of CFS/ME [40] [41]. Similarly, TRPV4 is expressed throughout the GI tract, primarily in sensory neurons of the colon [42] [43]. In rodent models of colitis and in human colonic tissue from patients with IBS, TRPV4 is upregulated in epithelial cells and lymphocyte infiltrates [44]. Additionally, increased mast cell and CD3+ lymphocytes are found in the lamina propria in close proximity to enteric nerve fibres [19] [43]. Studies indicate that mast cell regulators (histamine and tryptase) can exacerbate nociceptive responses in IBS via afferent enteric neurons [43]. Interestingly, we have identified abnormalities in mast cell function in CFS/ME that may contribute to GI dysfunction as histamine and tryptase are agonists of TRPV4 [28]. Although the current investigation only reports significant changes in TRPM3, further examination of TRPV1 and TRPV4 is warranted.

We observed significantly less mAChRM3 expression in the mucosal lymphocytes in the CFS/ME patient compared with the non-fatigued control. Interestingly, one of the SNP intron variants (rs7520974) we identified previously is associated with gastric smooth muscle contraction [30] [45]. While a paucity of information exists on the interactions between mAChRM3 and TRP ion channels, further investigations are needed given recent studies have outlined the antagonistic effect of phospholipase C coupled mACHR M1 receptor on TRPM3 in HEK-M3 cells [46] [47].

In this present investigation, we observed no difference in IL-1α expression in the CFS/ME patient compared to NFC. While lymphocyte phenotype populations were not investigated in our study, a precedent of altered CD8+ T cell, and
particularly NK cell function in CFS/ME exists [48] [49]. Certain NK cell subsets in CFS/ME exhibit altered cytokine production [48]. In the periphery, CD56\textsuperscript{bright} NK cells produce IFNγ, TNFβ, IL-13 and IL-10 during innate immune responses [50]. In a longitudinal analysis of NK cell phenotypes in CFS/ME we found a decrease in CD56\textsuperscript{bright} CD16-NK cells over time. In this same study IFNγ, TNFα and IL-10 expression were significantly increased [13] [48]. In a retrospective network analysis of cytokines in CFS/ME, Broderick et al. described the presence of a tight knit cluster of association and interaction between cytokines IL-1β, IL-4, IFNγ and TNFα. Median IL-4 concentrations in this study were increased 3-fold in CFS/ME groups while IL-2, IFNγ and TNFα concentrations remained unchanged. This finding supports the presence of an active Th2 profile and an antagonistic role of IL-4 towards Th1 cytokines IFNγ and TNFα [18]. While we did not examine IL-4, the aforementioned findings may explain the low level expression of IFNγ in our investigation via Th2 cytokine antagonism. We have described the expression of other inflammatory cytokines in previous studies [48] and further examination of an expanded cytokine array in small intestinal tissues of CFS/ME is warranted.

There was no expression of TNFα in the CFS/ME patient. In contrast, the NFC exhibited high levels of TNFα expression. In CFS/ME and IBS, elevated systemic levels of TNFα are common [34] [51]. In the current study, the high degree of complementary alternative medicines (CAMs) taken by the patient may have contributed to the reduction in inflammation, particularly TNFα [52].

This is the first assessment of small intestinal biopsy sample from a CFS/ME patient, as acquisition of samples is a particular challenge and is not routinely collected in this illness. Hence, the current study represents a specific case of CFS/ME and future directions would aim to assess these findings in a larger case-control study design. While we observed a reduction in a small subset of inflammatory markers, further studies using a larger array of cytokines will further elucidate the immunological signature of CFS/ME. The findings in this pilot study warrant future investigation into TRPV1, TRPV4, TRPM3 and mAChR expression in the small intestine in CFS/ME.

Acknowledgements

The authors would like to acknowledge the contribution of the Gold Coast Health and Medical Research Foundation, Stafford Fox Medical Research Foundation, Mr Douglas Stutt, Alison Hunter Memorial Foundation and Charity for Change for M.E.

List of Abbreviations

AChR, acetylcholine receptors; mAChRM3, acetylcholine muscarinic receptor M3; CFS/ME, chronic fatigue/myalgic encephalomyelitis; GI, gastrointestinal tract (GI); IL-1α interleukin 1 alpha; IFNγ, interferon gamma; IBS, irritable bowel syndrome; NFC, non-fatigued control; TRPV1, transient receptor poten-
tial vanilloid receptor 1; TRPV4, transient receptor potential vanilloid receptor 4; TRPM3, transient receptor potential melastatin 3; TNFα, tumour necrosis factor alpha.

Ethics Approval and Consent to Participate

All participants consented to participation and ethics approval for this study was given by Griffith University (MSC/05/HREC).

Consent for Publication

All participants consented to the publication of results.

Availability of Data and Materials

The data set during and/or analysed during the current study are available from the corresponding author on reasonable request.

Conflict of Interests

The authors declare they have no conflict of interests.

Funding

Gold Coast Health and Medical Research Foundation, Stafford Fox Medical Research Foundation, Mr Douglas Stutt, Alison Hunter Memorial Foundation and Charity for Change for M.E.

Authors’ Contributions

DS and SMG developed the aims and concepts of this project. MF and VG designed the experiments. MF performed the experiments and analysed data. SMG, DS and MF wrote the paper. All authors critically reviewed the paper.

References


[31] Fukuda, K., Straus, S.E. Hickie, I., Sharpe, M.C., Dobbins, J.G. and Komaroff, A.


